Denosumab delays metastases in castrate-resistant prostate cancer

Wednesday 2 November 2011

The monoclonal antibody Denosumab has been shown in a recent analysis to delay bone metastases in patients with castrate-resistant prostate cancer. Unfortunately, the results did not amount to an overall survival advantage, though there are tangible quality-of-life benefits.

>> http://www.oncologystat.com/news/Denosumab_Delays_Bone_Metastases_in_Castrate-Resistant_Prostate_Cancer_US.html


Further information

European Oncology Nursing Society
Avenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu